Frontier Small Caps

Aduro pleased to provide shareholders with an update on some of the Company's most significant developments since the start of 2022.

Rakovina highlighted the development of its kt-3000 drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tutors..

This is the largest and highest-resolution magnetic survey completed in the history of the area.

FDA has granted the request for a meeting to review the clinical trial protocol for its Phase 3 study in high-risk COVID-19 outpatients.